Peregrine Pharmaceuticals (NASDAQ:PPHM) recently announced that the novel exosome-based cancer detection platform proof-of-concept data showed positive results. The study, which was conducted in University of Texas Southwestern Medical Center, depicted the positive results. According to the study, the researchers proved that levels of exosomes containing phosphatidylserine (PS) found in plasma can help in differentiating between healthy patients and the ones with ovarian tumors.
The details about proof-of-concept data
The company also analysed the PS-positive exosome levels, which demonstrated that differences between malignant and benign tumors. The data was published in Oncotarget, under the title, “Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof-of-concept study.”
Peregrine Pharmaceuticals’ cancer diagnostic technology study
The company, at present, is moving to the next step for its proprietary cancer diagnostic technology, which is primarily based on exosome. The company received the license of its proprietary technology from UT Southwestern Medical Center in July, 2016. Through its technology, Peregrine Pharmaceuticals hopes to create its own optimized test, which would further assist in clinical testing.
Looking for strategic partner
In order to further advance its efforts, the company is also looking forward to collaborative suitors for development and commercialization of its technology. This proprietary cancer diagnostic technology works on diagnostic potential of the tumor exosomes. These tumor exosomes are smaller vesicles originating from tumor cells, which are then released in the blood on growth of tumors.
The president and chief executive officer of Peregrine Pharmaceuticals, Steven W. King said, “While the work is still early, we think these data serve as an important first step in highlighting the diagnostic potential of this platform.” He further added that the technology will play a vital role in areas like ovarian cancer, where there are limited screening options.
The company stated that they will explore further potential of this platform in not just ovarian cancer, but also other kinds of cancers.